Compare Gilead Sciences, Inc. (GILD) vs NEOS S&P 500 High Income ETF (SPYI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs NEOS S&P 500 High Income ETF — how do they compare? Gilead Sciences, Inc. trades at $147 (market cap $182.09B), while NEOS S&P 500 High Income ETF trades at $53.98 (market cap $12.51B). The key difference: Gilead Sciences, Inc. is far larger — about 14.6× NEOS S&P 500 High Income ETF's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while NEOS S&P 500 High Income ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and NEOS S&P 500 High Income ETF for 57 Days on average.
| GILD | SPYI | |
|---|---|---|
Market Cap | $182.09B | $12.51B |
Volume | 4,960,247 | 2,751,602 |
Sector | Health | Income / Options Overlay |
52-Week High | $155.80 | $54.42 |
52-Week Low | $116.74 | $47.98 |
Typical Hold Time | 111 Days | 57 Days |
Enterprise Value | $205.15B | — |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.10, up 1.99% with bullish technical signals and strong analyst support. The stock shows mixed fundamentals with a P/E of 17.84 and robust gross margins of 79.59%, though recent net income margin turned negative at -10.64%. Recent quarterly earnings beat expectations, and the company announced significant HIV prevention partnerships expanding access to lenacapavir across Latin America.
Outlook remains positive with 65% analyst buy ratings and $151.14 consensus target, though investors face risks from negative profitability metrics and increased investing outflows. The stock's current position near pivot point resistance at $147 suggests potential for breakout if earnings momentum continues.
SPYI trades at $54.01, down 0.13% with a bullish technical signal from moving averages. The ETF shows strong institutional interest as a covered-call income vehicle, though recent news highlights concerns about principal erosion from high-yield strategies. Technical indicators show RSI at overbought levels while support and resistance cluster around $54.
The outlook remains mixed with strong income generation potential offset by capital preservation risks. Recent coverage emphasizes the trade-off between high monthly distributions and potential long-term principal decline, requiring careful consideration for retirement income strategies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About NEOS S&P 500 High Income ETF
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →
